By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Corporate Headquarters
One Amgen Center Drive
Thousand Oaks  California  91320-1789  U.S.A.
Phone: 805-447-1000 Fax: 805-447-1010


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit, LinkedIn and follow us on


Key Statistics

Ownership: Public

Web Site: Amgen
Employees: 20,000
Symbol: AMGN

Company News
Organovo (ONVO) Sponsors Pioneering Research With Amgen (AMGN) And Medikine In Critical Areas Of Liver And Kidney Disease 8/23/2017 8:24:41 AM
Drug Giant Amgen (AMGN) Just Invested in This Massachusetts Machine Learning Biotech 8/23/2017 6:05:45 AM
Amgen (AMGN) To Present New Data From The Repatha (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017 8/21/2017 7:53:35 AM
Amgen (AMGN) And Humana (HUM) Partner For Improved Health Outcomes And Efficiency 8/18/2017 6:23:30 AM
Amgen (AMGN) Release: Repatha (Evolocumab) Phase III Cognitive Function Study Results Published In The New England Journal of Medicine 8/17/2017 6:15:13 AM
Amgen (AMGN) Announces 2017 Third Quarter Dividend 7/31/2017 1:25:52 PM
Amgen (AMGN) Submits Supplemental Biologics License Application For Prolia (denosumab) In Glucocorticoid-Induced Osteoporosis 7/31/2017 8:50:36 AM
Amgen (AMGN) And Allergan (AGN) Submit Biosimilar Biologics License Application For ABP 980 To FDA 7/31/2017 8:49:36 AM
FDA Grants Priority Review For Amgen (AMGN)'s Supplemental Biologics License Application For Repatha (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events 7/28/2017 8:05:01 AM
Amgen (AMGN) Falls After Earnings Update Reveals Embarassingly 'Bare' Pipeline 7/26/2017 8:27:29 AM